Compare Packaging Corporation of America (PKG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Packaging Corporation of America vs Vertex Pharmaceuticals Incorporated — how do they compare? Packaging Corporation of America trades at $231.22 (market cap $20.25B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.3× Packaging Corporation of America's market cap, and Packaging Corporation of America pays a 2.64% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Packaging Corporation of America for 45 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PKG | VRTX | |
|---|---|---|
Market Cap | $20.25B | $128.16B |
Volume | 491,102 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $257.43 | $557.96 |
52-Week Low | $191.68 | $407.37 |
Typical Hold Time | 45 Days | 120 Days |
Enterprise Value | $24.06B | $122.29B |
Dividend Yield | 2.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Packaging Corporation of America (PKG) trades at $227.25, down 1.08% with bearish technical signals despite recent earnings beats. The company maintains solid fundamentals with $9.5B revenue projection for 2026 and 7.25% net margin, though facing margin compression from cost pressures. Recent institutional buying by BlackRock and Bank of New York Mellon contrasts with mixed analyst ratings.
PKG offers steady packaging demand exposure but faces headwinds from rising input costs and competitive pressures. The 19.8% upside to consensus price target of $272.43 presents opportunity, though investors should monitor Q3 2026 earnings results on October 22 for margin trajectory confirmation amid bearish technical indicators.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
